Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BriaCell Therapeutics Corp (BCTXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: BCTXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -85.19% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.08M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.72 | 52 Weeks Range 0.02 - 0.70 | Updated Date 06/18/2025 |
52 Weeks Range 0.02 - 0.70 | Updated Date 06/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -131.54% | Return on Equity (TTM) -688.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 5776754 |
Shares Outstanding - | Shares Floating 5776754 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
BriaCell Therapeutics Corp
Company Overview
History and Background
BriaCell Therapeutics Corp is a biotechnology company focused on developing novel immunotherapies to fight cancer. Founded to develop and commercialize targeted and effective approaches for the management of cancer.
Core Business Areas
- Cancer Immunotherapy Development: Developing and commercializing targeted and effective immunotherapy approaches for managing cancer, specifically focused on advanced breast cancer. Focus on Bria-IMTu2122 and Bria-OTSu2122.
Leadership and Structure
Leadership includes Dr. William V. Williams (President & CEO), and experienced scientists and business executives. Organized into research and development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- Bria-IMTu2122: Immunotherapy designed to activate the patient's immune system to fight cancer cells. Clinical trials are ongoing, and market share data is not yet available as it's not yet approved for sale. Competitors include companies developing checkpoint inhibitors and other immunotherapies, such as Merck (MRK), Bristol Myers Squibb (BMY), and Roche (RHHBY).
- Bria-OTSu2122: Off-the-shelf personalized immunotherapy, market share data is not yet available as it's not yet approved for sale. Competitors include companies developing personalized cancer vaccines such as Moderna (MRNA) and BioNTech (BNTX).
Market Dynamics
Industry Overview
The cancer immunotherapy market is experiencing substantial growth driven by advances in understanding the immune system and cancer biology. The market is characterized by intense competition, high R&D investment, and regulatory scrutiny.
Positioning
BriaCell is positioned as an innovative immunotherapy company focusing on personalized and targeted approaches for advanced breast cancer. Their competitive advantage lies in their unique immunotherapy platform and focus on challenging-to-treat cancers.
Total Addressable Market (TAM)
The global cancer immunotherapy market is estimated to reach hundreds of billions of dollars. BriaCell is positioned to capture a share of this TAM by targeting specific cancer types with unmet needs.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy platform (Bria-IMTu2122 and Bria-OTSu2122)
- Focus on challenging-to-treat cancers
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- High regulatory hurdles
- Lack of approved products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Positive clinical trial results
- Breakthrough Therapy designation from regulatory agencies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory setbacks
- Economic downturn
Competitors and Market Share
Key Competitors
- MRK
- BMY
- RHHBY
- MRNA
- BNTX
Competitive Landscape
BriaCell faces intense competition from larger pharmaceutical companies with greater resources and established market presence. BriaCell's advantage lies in its innovative technology and focus on specific unmet needs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by advancements in their clinical programs and financing activities.
Future Projections: Future growth is dependent on the success of clinical trials and regulatory approvals. Analyst estimates vary widely due to the inherent uncertainty of biotechnology investments.
Recent Initiatives: Recent initiatives include advancing clinical trials for Bria-IMTu2122 and Bria-OTSu2122, securing additional financing, and exploring potential partnerships.
Summary
BriaCell Therapeutics is a high-risk, high-reward biotechnology company focused on innovative cancer immunotherapies. The company's success hinges on positive clinical trial outcomes and regulatory approvals. BriaCell needs to address its limited financial resources and mitigate the risks associated with clinical development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website, SEC filings, press releases, analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment in biotechnology companies is highly speculative and involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BriaCell Therapeutics Corp
Exchange NASDAQ | Headquaters West Vancouver, BC, Canada | ||
IPO Launch date 2021-02-24 | CEO, President & Director Dr. William V. Williams FCPA, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://briacell.com |
Full time employees - | Website https://briacell.com | ||
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.